Fig. 5: TXNIP inhibited the expression of cMYC targets and protein UFMylation.
From: BRD4 inhibition suppresses histone H4 UFMylation to increase ferroptosis sensitivity through TXNIP
A RT-qPCR analysis of the mRNA levels of CYCLIN A2, MAD2, ORC2, MCM6, and SSBP1 in Control and TXNIP KO cells treated with DMSO and 2 μM JQ1. B The protein levels of CYCLIN A2, B1, D1, and MAD2 in Control and TXNIP KO cells treated with DMSO and 2 μM JQ1. C GSEA analysis of gene expression in cells with DMSO and 2 μM JQ1 treatment indicated that cMYC target genes were downregulated in JQ1 treated cells. D The enrichment of cMYC at the promoters of CYCLIN A2, MAD2, ORC2, MCM6, and SSBP1 in Control and TXNIP KO cells with or without JQ1 treatment. E The expression of cMYC in Control and TXNIP KO cells after JQ1 treatment. F The level of protein UFMylation in Control and TXNIP KO cells with 2 μM JQ1 treatment. G The enrichment of UFMylated proteins at the promoters of CYCLIN A2, MAD2, ORC2, MCM6, and SSBP1 in Control and TXNIP KO cells with or without JQ1 treatment. H The protein levels of CYCLIN A2, MAD2, and total protein UFMylation in cells with 30 μM DKM 2-93 treatment. I The mRNA levels of CYCLIN A2, MAD2, ORC2, MCM6, and SSBP1 in cells treated with DMSO and 30 μM DKM 2-93. ****p value < 0.001, ***p value < 0.005, **p value < 0.01, *p value < 0.05 (one-way ANOVA test in A, D, and G; two-tailed unpaired Student t test in I); ns not significant.
